Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH)

FairStock Score: 95/100 — HIGH CONVICTION

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn real cash and sell at sensible prices. Aurinia is a small biotech focused on autoimmune disease, with LUPKYNIS as its marketed therapy. The filed numbers show a real turn. In FY2023, revenue was $175.5M and net income was -$78.0M. In FY2024, revenue was $235.1M and net income was $5.8M. In FY2025, revenue was $283.1M and net income was $287.2M. The latest quarters continued that progress: fiscal Q1 2026, the quarter ended 2026-03-31, revenue $77.7M and net income $34.4M; fiscal Q2 2026, the quarter ended 2026-06-30, revenue $83.2M and net income $37.4M. FairStock estimates trailing free cash flow of $175.1M, an 8.0% FCF yield. Debt is low at D/E 0.10, Altman Z is 7.31, and ROE is 66.12%.

In plain English: Aurinia Pharmaceuticals makes a medicine for lupus nephritis, a kidney disease, and is developing another drug for autoimmune conditions. The business looks strong: sales and profits have grown, debt is low, and it generates a lot of cash. At $16.36, the shares look cheap compared with recent profits, but they are a little above a conservative value estimate, so they seem cheap-to-fair rather than a deep bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q4 2025 10-K (period ended 2025-12-31) · fiscal Q3 2025 10-K (period ended 2025-09-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer